Syra Health shareholders back directors and equity plan

Syra Health Corp. held its Annual Meeting of Stockholders on July 23, 2026, with 13,664,105 shares of common stock represented, including 350,000 Class B shares carrying 16.5 votes per share, constituting a quorum.

Rhea-AI Filing Summary

Syra Health Corp. held its Annual Meeting of Stockholders on July 23, 2026, with 13,664,105 shares of common stock represented, including 350,000 Class B shares carrying 16.5 votes per share, constituting a quorum.

Stockholders elected all five director nominees to serve until the 2027 annual meeting. They also ratified M&K CPAs, PLLC as independent registered public accounting firm for the fiscal year ended December 31, 2026, with 12,133,305 votes in favor. In addition, stockholders approved an amendment to the Company's 2022 Omnibus Equity Incentive Plan, increasing the number of Class A shares available for issuance to 4,100,000, with 8,548,265 votes for and 2,691,142 against.

Filing Explained

The July 23 vote approved expanding the 2022 Omnibus Equity Incentive Plan’s Class A share capacity to 4,100,000, creating room for future plan issuances; the filing does not report that these shares were issued or that existing holders were diluted.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Shares represented at meeting: 13,664,105 shares Class B voting power: 350,000 shares; 16.5 votes per share Auditor ratification votes for: 12,133,305 votes +2 more

5 metrics

Shares represented at meeting 13,664,105 shares Shares of common stock represented in person or by proxy at the July 23, 2026 annual meeting

Class B voting power 350,000 shares; 16.5 votes per share Class B common stock included in meeting quorum, each share carrying 16.5 votes

Auditor ratification votes for 12,133,305 votes Votes in favor of ratifying M&K CPAs, PLLC as auditor for fiscal year ended December 31, 2026

Equity plan pool after amendment 4,100,000 Class A shares Number of Class A shares available for issuance under the 2022 Omnibus Equity Incentive Plan after amendment

Equity plan amendment votes for 8,548,265 votes Votes in favor of amending the 2022 Omnibus Equity Incentive Plan

Key Terms

Broker Non Vote, 2022 Omnibus Equity Incentive Plan, independent registered public accounting firm

3 terms

Broker Non Vote financial

"For | Against | Abstain | Broker Non Vote 8,548,265 | 2,691,142 | 452 | 2,424,246"

When a broker holds shares for a client but does not have the client’s instructions to vote on a particular corporate matter, the broker often cannot cast a ballot; this is called a broker non-vote. It matters to investors because those uncast votes can change whether proposals pass, especially on important governance or merger issues, so active voting by investors can directly influence company decisions like a missing voice in a group vote.

2022 Omnibus Equity Incentive Plan financial

"The amendment to the Company’s 2022 Omnibus Equity Incentive Plan increasing the number"

independent registered public accounting firm financial

"The appointment of M&K CPAs, PLLC, as the Company’s independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Syra Health (SYRA) stockholders vote on at the July 23, 2026 annual meeting?

Stockholders elected five directors, ratified M&K CPAs, PLLC as auditor for 2026, and approved an amendment to the 2022 Omnibus Equity Incentive Plan increasing available Class A shares to 4,100,000.

How many Syra Health (SYRA) shares were represented at the 2026 annual meeting?

A total of 13,664,105 shares of common stock were represented in person or by proxy, including 350,000 Class B shares with each Class B share carrying 16.5 votes, establishing a quorum for conducting business.

Were all Syra Health (SYRA) director nominees elected in 2026?

Yes. All five director nominees received sufficient votes for election, with each nominee, including Priya Prasad and Dr. Vijayapal R. Reddy, receiving over 9.4 million votes for and no votes recorded against.

Did Syra Health (SYRA) stockholders approve the 2022 Omnibus Equity Incentive Plan amendment?

Yes. Stockholders approved the amendment to the 2022 Omnibus Equity Incentive Plan, increasing Class A shares available for issuance to 4,100,000, with 8,548,265 votes for and 2,691,142 votes against plus broker non-votes.

Was M&K CPAs, PLLC ratified as Syra Health (SYRA) auditor for 2026?

Yes. Stockholders ratified M&K CPAs, PLLC as the independent registered public accounting firm for the fiscal year ended December 31, 2026, with 12,133,305 votes for, 48,079 against, and 1,482,721 abstentions.

What is the voting power of Syra Health (SYRA) Class B common stock?

The Company reported 350,000 shares of Class B common stock outstanding at the meeting, with each Class B share entitled to 16.5 votes, giving these shares higher voting power than standard common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/23/2026 - 04:15 PM Accepted by SEC EDGAR 07/23/2026 - 04:15 PM Learn about SEC filing dates

false 0001922335 0001922335 2026-07-23 2026-07-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 23, 2026

SYRA HEALTH CORP.

(Exact name of registrant as specified in its charter)

Delaware		001-41822		85-4027995
(State or other jurisdiction		(Commission		(I. R. S. Employer
of incorporation)		File Number)		Identification No.)

1119 Keystone Way N. #201

Carmel, IN 46032

(Address of principal executive offices, including zip code)

(463) 345-8950

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, $0.001 par value		SYRA		OTCQB

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders

On July 23, 2026, Syra Health Corp. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). A total of 13,664,105 shares of common stock (including 350,000 shares of Class B common stock with each share of Class B common stock having 16.5 votes per share), constituting a quorum, were represented in person or by valid proxies at the Annual Meeting. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting, as set forth in the Definitive Proxy Statement, filed with the Securities and Exchange Commission on June 1, 2026 are as follows:

Proposal 1. All of the five (5) nominees for director were elected to serve until the 2027 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the five (5) directors was as follows:

Directors		For		Against		Abstain		Broker Non Vote
Priya Prasad		9,583,429		-		1,656,430		2,424,246
Dr. Vijayapal R. Reddy		9,583,379		-		1,656,480		2,424,246
Dr. Ketan Paranjape		9,583,411		-		1,656,448		2,424,246
Dr. Avutu S. Reddy		9,583,354		-		1,656,505		2,424,246
Radhika Mereddy		9,416,873		-		1,822,986		2,424,246

Proposal 2. The appointment of M&K CPAs, PLLC, as the Company’s independent registered public accounting firm for its fiscal year ended December 31, 2026 was ratified and approved by the stockholders by the votes set forth in the table below:

For		Against		Abstain		Broker Non Vote
12,133,305		48,079		1,482,721		-

Proposal 3. The amendment to the Company’s 2022 Omnibus Equity Incentive Plan increasing the number of Class A shares available for issuance to 4,100,000 was approved by the stockholders by the votes set forth in the table below:

For		Against		Abstain		Broker Non Vote
8,548,265		2,691,142		452		2,424,246

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SYRA HEALTH CORP.
Date: July 23, 2026	By:	/s/ Priya Prasad
		Priya Prasad
		Chief Financial Officer

-3-

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB